- Home
- ABEO vs TRUE Comparison
ABEO vs TRUE Comparison
Compare ABEO & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- TRUE
- Stock Information
- Founded
- ABEO N/A
- TRUE 2005
- Country
- ABEO United States
- TRUE United States
- Employees
- ABEO N/A
- TRUE N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- TRUE Computer Software: Programming Data Processing
- Sector
- ABEO Health Care
- TRUE Technology
- Exchange
- ABEO Nasdaq
- TRUE Nasdaq
- Market Cap
- ABEO 237.4M
- TRUE 213.8M
- IPO Year
- ABEO 1980
- TRUE 2014
- Fundamental
- Price
- ABEO $4.92
- TRUE $1.29
- Analyst Decision
- ABEO Strong Buy
- TRUE Buy
- Analyst Count
- ABEO 5
- TRUE 4
- Target Price
- ABEO $17.00
- TRUE $4.17
- AVG Volume (30 Days)
- ABEO 834.1K
- TRUE 338.9K
- Earning Date
- ABEO 05-14-2025
- TRUE 04-28-2025
- Dividend Yield
- ABEO N/A
- TRUE N/A
- EPS Growth
- ABEO N/A
- TRUE N/A
- EPS
- ABEO N/A
- TRUE N/A
- Revenue
- ABEO N/A
- TRUE $175,598,000.00
- Revenue This Year
- ABEO N/A
- TRUE $16.39
- Revenue Next Year
- ABEO $539.93
- TRUE $17.70
- P/E Ratio
- ABEO N/A
- TRUE N/A
- Revenue Growth
- ABEO N/A
- TRUE 10.64
- 52 Week Low
- ABEO $3.05
- TRUE $1.29
- 52 Week High
- ABEO $8.45
- TRUE $4.62
- Technical
- Relative Strength Index (RSI)
- ABEO 51.29
- TRUE 29.90
- Support Level
- ABEO $3.93
- TRUE $1.30
- Resistance Level
- ABEO $5.02
- TRUE $1.35
- Average True Range (ATR)
- ABEO 0.41
- TRUE 0.13
- MACD
- ABEO 0.06
- TRUE 0.01
- Stochastic Oscillator
- ABEO 90.83
- TRUE 7.69
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.